Peter Chin

Peter leads the Late Clinical function at Denali. In this role, he coordinates late stage clinical science and medical affairs activities as the portfolio advances through the lifecycle. His group facilitates the design and oversight of late stage clinical trials to support regulatory approval, augments the medical community’s understanding of neurological disease mechanisms, and characterizes the evidence base to support appropriate use of new therapeutics upon approval.

Peter most recently served as Group Medical Director for Neuroscience in U.S. Medical Affairs at Genentech and previously held leadership roles in neuroscience development at Genentech/Roche and Novartis, contributing to the global development and clinical application of therapies approved for relapsing and progressive forms of multiple sclerosis, including fingolimod, siponimod and ocrelizumab. For over a decade he has also engaged in advancing clinical research platforms through initiatives sponsored by NIH-NINDS, C-PATH, patient advocacy groups, and various academic-industry consortia.

Peter completed his B.A. in Molecular and Cell Biology at the University of California at Berkeley, M.D. at Dartmouth, neurology residency at the University of Washington, and fellowship as a Robert Wood Johnson Foundation Clinical Scholar at UCLA, where he also obtained an M.S. in Health Services through the School of Public Health.